Company news
Dianthus Therapeutics, Inc. news in 2021
Dianthus Therapeutics, Inc.'s news releases, calls and decks from 2021, newest first.
Magenta Therapeutics Highlights Presentations of Data Related to Stem Cell Mobilization and Targeted Conditioning at the 2021 American Society of Hematology (ASH) Annual Meeting
December 13, 2021
Magenta Therapeutics Reports Third Quarter Financial Results and Program Highlights
November 3, 2021
Magenta Therapeutics Announces Data Presentations Related to its Mobilization and Conditioning Programs at the 2021 American Society of Hematology (ASH) Annual Meeting
November 3, 2021
Magenta Therapeutics Appoints Jeffrey Humphrey, M.D. as Chief Medical Officer
October 3, 2021
Magenta Therapeutics to Participate in 2021 Cantor Virtual Global Healthcare Conference
September 20, 2021
Magenta Therapeutics Announces IND Clearance for MGTA-117 Targeted Conditioning Clinical Trial
September 14, 2021
Magenta Therapeutics to Participate in Upcoming Healthcare Investor Conferences in August
August 2, 2021
Magenta Therapeutics Announces Update on U.S. FDA Investigational New Drug Application for MGTA-117 in Patients with Acute Myeloid Leukemia and Myelodysplastic Syndrome
July 20, 2021
Magenta Therapeutics Appoints Caren Deardorf as Chief Commercial Officer
July 5, 2021
Magenta Therapeutics Appoints Thomas Beetham as Chief Legal Officer
June 13, 2021
Magenta Therapeutics Announces Additional Preliminary Positive Results from Ongoing Phase 2 Clinical Trial of MGTA-145 and Plerixafor in Patients with Multiple Myeloma at the American Society of Clinical Oncology (ASCO) Annual Meeting
June 3, 2021
Magenta Therapeutics to Participate in Goldman Sachs 42nd Annual Global Healthcare Conference
June 2, 2021
Magenta Therapeutics to Participate in Upcoming Healthcare Investor Conferences in May
May 13, 2021
Magenta Therapeutics Announces Positive Preliminary Results from Phase 2 Clinical Trial of MGTA-145 in Multiple Myeloma and Provides an Update on its Anticipated Clinical Study with MGTA-117
May 11, 2021
Magenta Therapeutics Announces $86.4 Million Common Stock Investment from Multiple Investors
May 11, 2021
Magenta Therapeutics Reports First Quarter Financial Results and Recent Program Highlights
May 5, 2021
Magenta Therapeutics Appoints David Nichols as Chief Technical Officer
April 18, 2021
Magenta Therapeutics to Participate in the Guggenheim Healthcare Talks 2021 Genomic Medicines & Rare Disease Conference
March 24, 2021
Magenta Therapeutics Presents Final Phase 1 Results of MGTA-145 Stem Cell Mobilization Clinical Trial and Preclinical Data from Targeted Conditioning Program at the European Society for Blood and Marrow Transplantation (EBMT) 2021 Annual Meeting
March 14, 2021
Magenta Therapeutics to Present at the Oppenheimer 31st Annual Healthcare Conference
March 8, 2021
Magenta Therapeutics Reports Fourth Quarter and Full-Year 2020 Financial Results and Recent Program Highlights
March 2, 2021
Magenta Therapeutics to Present Additional Data from Phase 1 MGTA-145 Stem Cell Mobilization Program and Preclinical Updates on Targeting Conditioning Program at Transplantation and Cellular Therapy (TCT) 2021 Annual Meeting
February 7, 2021
Magenta Therapeutics Highlights Recent Progress and Expected Timing of 2021 Milestones, Including Four Ongoing and Planned Clinical Trials
January 10, 2021
Magenta Therapeutics to Present at the 39th Annual J.P. Morgan Healthcare Conference
January 4, 2021